Ciprobay

Ciprobay

ciprofloxacin

Manufacturer:

Bayer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ciprofloxacin
Indications/Uses
Infections of resp tract, middle ear, paranasal sinuses, eyes, kidneys &/or efferent urinary tract, genital organs, abdominal cavity, skin & soft tissues, bones & joints; sepsis, prophylaxis of infections & selective intestinal decontamination in immunosuppressed patients. Oral: Prophylaxis of invasive infections due to N meningitidis. Inhalational anthrax in adults & childn.
Dosage/Direction for Use
Tab Adult Resp tract infection 500-750 mg bd for 7-14 days. Acute & uncomplicated UTI 250-500 mg bd for 7 days. Cystitis in women 500 mg as single dose. Complicated UTI 500-750 mg bd for 7 days. Uncomplicated gonorrhea 500 mg once daily. Adnexitis, prostatitis, epididymo-orchitis 500-750 mg bd for 7-14 days. Diarrhea 500 mg bd for 7 days. Other infections 500 mg bd for 7-14 days. Severe, life-threatening infections 750 mg bd for 10 days. Inhalational anthrax (post-exposure) 500 mg bd. Prophylaxis of invasive infections due to N meningitidis 500 mg as single dose. Infusion soln Resp tract infection 400 mg bd-tds for 7-14 days. Acute & uncomplicated UTI 200-400 mg bd for 7 days. Complicated UTI 400 mg bd-tds for 7 days. Adnexitis, prostatitis, epididymo-orchitis 400 mg bd-tds for 7-14 days. Diarrhea 400 mg bd for 7 days. Other infections 400 mg bd for 7-14 days. Severe, life-threatening infections 400 mg tds for 10 days.
Administration
May be taken with or without food: May be taken on an empty stomach for better absorption. Do not take w/ dairy products (eg, milk, yoghurt) or mineral-fortified fruit juice (eg, Ca-fortified orange juice).
Contraindications
Hypersensitivity to quinolones. Co-administration w/ tizanidine.
Special Precautions
Not recommended for pneumococcal infections. QT interval prolongation; pseudomembranous colitis, myasthenia gravis, history of quinolone-related tendon disorders, CNS disorders which may predispose seizure. Concomitant use w/ other CYP450 1A2 enzyme inhibitor. Patients receiving class IA or class III antiarrhythmics, TCAs, macrolides, antipsychotics or drugs that prolong QT interval. Avoid exposure to direct excessive sunlight. Discontinue treatment if signs & symptoms of hepatic disease occur. May affect ability to drive or operate machinery. Not recommended during pregnancy & lactation. Childn & adolescents w/ renal or hepatic impairment. Elderly.
Adverse Reactions
Nausea, diarrhea, inj & infusion site reactions, vomiting, transient increased transaminases, rash, arthralgia.
Drug Interactions
Class IA or III antiarrhythmics, multivalent cation-containing prep & mineral supplements, polymeric phosphate binders, sucralfate or antacids, highly buffered drugs containing Mg, Al, Ca, dairy products or mineral fortified drinks. Increased serum conc w/ probenecid. Increased serum conc of tizanidine, theophylline, caffeine, pentoxifylline. Increased absorption w/ metoclopramide. Slight reduction of Cmax & AUC w/ omeprazole. Inhibit renal tubular transport of methotrexate. Induced convulsions w/ NSAIDs. Increased serum creatinine conc w/ cyclosporin. Augmented anticoagulant effects of vit K antagonist. Intensified action of glibenclamide. Increased AUC & Cmax of duloxetine, ropinirole & sildenafil. Reduced clearance of lidocaine IV.
MIMS Class
ATC Classification
J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Presentation/Packing
Form
Ciprobay infusion 200 mg/100 mL
Packing/Price
1's
Form
Ciprobay infusion 100 mg/50 mL
Packing/Price
1's
Form
Ciprobay tab 250 mg
Packing/Price
10's
Form
Ciprobay tab 500 mg
Packing/Price
10's
Form
Ciprobay infusion 400 mg/200 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in